1Puhan MA, Van Natta ML, Palella FJ, Addessi A, Meinert C. Excess Mortality in Patients with AIDS in the Era of Highly Active Antiretroviral Therapy: Temporal Changes and Risk Factors. Clinical Infectious Diseases,2010,51:947.
2Montaner J, Hogg R, Yip B, Chan K, Craib K, O'Shaughnessy M. To start or not to start? Diminished effectiveness of anti-retroviral therapy among patients initiating therapy with CD4 + cell counts below 200/ mm3. 2000. p. 45 (abstract no. LbPeB7050).
3Palella FJ, Deloria-Knoll M, Chmiel JS, Moor- man AC, Wood KC, Greenberg AE, et al. Survival ben- efit of initiating antiretroviral therapy in HIV-infected persons in different CD4+cell strata. Annals of internal medicine,2003,138:620.
4Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Guidelines for Using Antiretroviral Agents a- mong HIV-Infected Adults and Adolescents: The Panel on Clinical Practices for Treatment of HIV. Annals of internal medicine,2002,137:381.
5Freedberg KA, Scharfstein JA, Seage GR, Losina E, Weinstein MC, Craven DE, et al. The cost- effectiveness of preventing AIDS-related opportunistic infections. JAMA: The Journal of the American Medical Association, 1998,279:130.
7Fang CT, Chang YY, Hsu HM, Twu SJ, Chen KT, Chen MY, et al. Cost-effectiveness of highly active antiretroviral therapy for HIV infection in Taiwan. J Formos Med Assoc ,2007,106:631-40.
8S.Loubiere,J.‐P.Moatti.Economic evaluation of point‐of‐care diagnostic technologies for infectious diseases[J].Clinical Microbiology and Infection.2010(8)
9Chi-Tai Fang,Yu-Yin Chang,Hsu-Mei Hsu,Shiing-Jer Twu,Kow-Tong Chen,Mao-Yuan Chen,Loreen Y.L. Huang,Jing-Shiang Hwang,Jung-Der Wang.Cost-effectiveness of Highly Active Antiretroviral Therapy for HIV Infection in Taiwan[J].Journal of the Formosan Medical Association.2007(8)
10R. L. Sowell,B. F. Seals,L. Moneyham,A. Demi,L. Cohen,S. Brake.Quality of life in HIV-infected women in the south-eastern United States[J].AIDS Care.1997(5)
